These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 30337520

  • 1. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
    Wei L, Ye H, Li G, Lu Y, Zhou Q, Zheng S, Lin Q, Liu Y, Li Z, Chen R.
    Cell Death Dis; 2018 Oct 18; 9(11):1065. PubMed ID: 30337520
    [Abstract] [Full Text] [Related]

  • 2. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L, Yao J, Li W, Zhang C.
    Oncol Res; 2018 Jul 05; 26(6):827-835. PubMed ID: 28477403
    [Abstract] [Full Text] [Related]

  • 3. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
    Moatassim-Billah S, Duluc C, Samain R, Jean C, Perraud A, Decaup E, Cassant-Sourdy S, Bakri Y, Selves J, Schmid H, Martineau Y, Mathonnet M, Pyronnet S, Bousquet C.
    Oncotarget; 2016 Jul 05; 7(27):41584-41598. PubMed ID: 27177087
    [Abstract] [Full Text] [Related]

  • 4. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H, Gao W, Li X, Yu L, Luo D, Liu Y, Yu X.
    Pancreatology; 2021 Apr 05; 21(3):589-598. PubMed ID: 33579599
    [Abstract] [Full Text] [Related]

  • 5. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
    Shang M, Weng L, Xu G, Wu S, Liu B, Yin X, Mao A, Zou X, Wang Z.
    J Cell Physiol; 2021 Oct 05; 236(10):6868-6883. PubMed ID: 33629745
    [Abstract] [Full Text] [Related]

  • 6. Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK.
    Toste PA, Nguyen AH, Kadera BE, Duong M, Wu N, Gawlas I, Tran LM, Bikhchandani M, Li L, Patel SG, Dawson DW, Donahue TR.
    Mol Cancer Res; 2016 May 05; 14(5):437-47. PubMed ID: 26979711
    [Abstract] [Full Text] [Related]

  • 7. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J, Yang J, Ramachandran V, Arumugam T, Deng D, Li Z, Xu L, Logsdon CD.
    PLoS One; 2015 May 05; 10(12):e0144969. PubMed ID: 26709920
    [Abstract] [Full Text] [Related]

  • 8. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer.
    Fang Y, Zhou W, Rong Y, Kuang T, Xu X, Wu W, Wang D, Lou W.
    Exp Cell Res; 2019 Oct 01; 383(1):111543. PubMed ID: 31374207
    [Abstract] [Full Text] [Related]

  • 9. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
    Su YH, Hsu TW, Chen HA, Su CM, Huang MT, Chuang TH, Leo Su J, Hsieh CL, Chiu CF.
    J Cell Physiol; 2021 Jun 01; 236(6):4420-4434. PubMed ID: 33184874
    [Abstract] [Full Text] [Related]

  • 10. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
    Peran I, Dakshanamurthy S, McCoy MD, Mavropoulos A, Allo B, Sebastian A, Hum NR, Sprague SC, Martin KA, Pishvaian MJ, Vietsch EE, Wellstein A, Atkins MB, Weiner LM, Quong AA, Loots GG, Yoo SS, Assefnia S, Byers SW.
    Gastroenterology; 2021 Mar 01; 160(4):1359-1372.e13. PubMed ID: 33307028
    [Abstract] [Full Text] [Related]

  • 11. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
    Xu BQ, Fu ZG, Meng Y, Wu XQ, Wu B, Xu L, Jiang JL, Li L, Chen ZN.
    Oncotarget; 2016 Sep 20; 7(38):62177-62193. PubMed ID: 27556697
    [Abstract] [Full Text] [Related]

  • 12. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G, Nemirovsky O, Gillespie JA, Karasinska JM, Kalloger SE, Supuran CT, Schaeffer DF, Bashashati A, Shah SP, Topham JT, Yapp DT, Li J, Renouf DJ, Stanger BZ, Dedhar S.
    Gastroenterology; 2019 Sep 20; 157(3):823-837. PubMed ID: 31078621
    [Abstract] [Full Text] [Related]

  • 13. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B, Xing F, Wang J, Wang X, Zhou C, Fan G, Zhuo Q, Ji S, Yu X, Xu X, Qin Y, Li Z.
    Cancer Lett; 2024 Oct 10; 602():217197. PubMed ID: 39216548
    [Abstract] [Full Text] [Related]

  • 14. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D, Shi J, Fu H, Wei Z, Xu J, Hu Z, Zhang Y, Yan R, Cai Q.
    Tumour Biol; 2016 Sep 10; 37(9):12315-12327. PubMed ID: 27289231
    [Abstract] [Full Text] [Related]

  • 15. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
    Pham NA, Tsao MS, Cao P, Hedley DW.
    Pancreas; 2007 Oct 10; 35(3):e16-26. PubMed ID: 17895832
    [Abstract] [Full Text] [Related]

  • 16. Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells.
    Zhang H, Wu H, Guan J, Wang L, Ren X, Shi X, Liang Z, Liu T.
    Oncotarget; 2015 Feb 20; 6(5):3085-97. PubMed ID: 25609203
    [Abstract] [Full Text] [Related]

  • 17. Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1-CD44 Axis.
    Nallasamy P, Nimmakayala RK, Karmakar S, Leon F, Seshacharyulu P, Lakshmanan I, Rachagani S, Mallya K, Zhang C, Ly QP, Myers MS, Josh L, Grabow CE, Gautam SK, Kumar S, Lele SM, Jain M, Batra SK, Ponnusamy MP.
    Gastroenterology; 2021 Dec 20; 161(6):1998-2013.e7. PubMed ID: 34418441
    [Abstract] [Full Text] [Related]

  • 18. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW.
    Mol Cancer; 2013 Sep 11; 12(1):104. PubMed ID: 24025152
    [Abstract] [Full Text] [Related]

  • 19. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X, Xie J, Lu X, Li H, Wen C, Huo Z, Xie J, Shi M, Tang X, Chen H, Peng C, Fang Y, Deng X, Shen B.
    Cancer Lett; 2017 Jul 28; 399():1-9. PubMed ID: 28428074
    [Abstract] [Full Text] [Related]

  • 20. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis.
    Hu C, Xia R, Zhang X, Li T, Ye Y, Li G, He R, Li Z, Lin Q, Zheng S, Chen R.
    Mol Cancer; 2022 Jan 19; 21(1):24. PubMed ID: 35045883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.